Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01336933 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
A Phase 2 study, sponsored by University of Nebraska.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT01336933 is a Phase 2 study that has completed, run by University of Nebraska. The registered enrollment target is 34 participants.
The verdict
NCT01336933, a Phase 2 study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
Interventions
- DRUG Vincristine
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG etoposide
- DRUG pralatrexate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2011-07-06 |
| Est. Completion | 2016-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01336933
The ClinicalTrials.gov registry entry for NCT01336933 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vincristine is the first listed.
NCT01336933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01336933 about?
NCT01336933 is a clinical study titled "Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma". This phase II trial studies how well combination chemotherapy and pralatrexate works in treating patients with non-Hodgkin lymphoma (NHL). Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
What is the current status of trial NCT01336933?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2011-07-06. Estimated completion is 2016-12-28.
What interventions are being tested in trial NCT01336933?
The interventions under investigation include: Vincristine (DRUG), prednisone (DRUG), cyclophosphamide (DRUG), etoposide (DRUG), pralatrexate (DRUG).
Who is sponsoring clinical trial NCT01336933?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.